Form 4: CytomX Therapeutics SVP, Chief Scientific Officer, Marcia Belvin, Sells Shares to Cover Tax Obligations

Marcia Belvin, SVP, Chief Scientific Officer of CytomX Therapeutics, sold 19,512 shares of common stock on March 18, 2025, to cover tax obligations related to vesting restricted stock units.

Summary

• Marcia Belvin, the SVP, Chief Scientific Officer of CytomX Therapeutics, sold 19,512 shares of common stock on March 18, 2025.
• The sale was executed at a price of $0.599 per share.
• The transaction was conducted to satisfy tax or other government withholding obligations related to the vesting of restricted stock units (RSUs).
• Following the transaction, Belvin directly owns 248,636 shares, which includes 158,958 RSUs.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction (sale of shares for tax obligations) and doesn't inherently indicate positive or negative sentiment regarding the company's performance or future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment of interests between management and shareholders.

Stakeholder Impact

• The sale of shares by an insider could have a minor negative impact on shareholder sentiment, but is unlikely to be significant given the stated reason for the sale.

Key Dates

Keywords

Form 4, CytomX Therapeutics, Marcia Belvin, Stock Sale, RSUs, Tax Obligations, Insider Trading